Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.
Dextromethorphan was granted FDA approval before 3 December 1957.
Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicated in the treatment of pseudobulbar affect.
Swedish American Neuro and Headache Center, Rockford, Illinois, United States
StudyMetrix Research, LLC, Saint Peters, Missouri, United States
Island Neurological Associates, PC, Plainview, New York, United States
Shands Hospital at University of Florida, Gainesville, Florida, United States
Einstein Division/Montefiore Medical Center, Bronx, New York, United States
Seoul National University Hospital, Seoul, Korea, Republic of
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States
Parexel, Baltimore, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.